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Abstract:  RPL23A gene encodes a ribosomal protein that is a component of the 60S 
subunit. The protein belongs to the L23P family of ribosomal proteins, which is located in 
the cytoplasm. The purpose of this paper was to explore the structure and anti-cancer 
function of ribosomal protein L23A ( RPL23A) gene of the Giant Panda (Ailuropoda 
melanoleuca). The cDNA of RPL23A was cloned successfully from the Giant Panda using 
RT-PCR technology. We constructed a recombinant expression vector containing RPL23A 
cDNA and over-expressed it in Escherichia coli using pET28a plasmids. The expression 
product obtained was purified by using Ni chelating affinity chromatography. 
Recombinant protein of RPL23A obtained from the experiment acted on Hep-2 cells and 
human HepG-2 cells, then the growth inhibitory effect of these cells was observed by MTT  
(3-[4,5-dimethyl-2-thiazolyl]-2,5-diphenyl-2H-tetrazolium  bromide) assay. The result 
indicated that the length of the fragment cloned is 506 bp, and it contains an open-reading 
frame (ORF) of 471 bp encoding 156 amino acids. Primary structure analysis revealed that 
the molecular weight of the putative RPL23A protein is 17.719 kDa with a theoretical  
pI 11.16. The molecular weight of the recombinant protein RPL23A is 21.265 kDa with a 
theoretical pI 10.57. The RPL23A gene can be really expressed in E. coli and the RPL23A 
protein, fusioned with the N-terminally His-tagged protein, gave rise to the accumulation 
of an expected 22 KDa polypeptide. The data showed that the recombinant protein 
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RPL23A had a time- and dose-dependency on the cell growth inhibition rate. The data also 
indicated that the effect at low concentrations was better than at high concentrations on 
Hep-2 cells, and that the concentration of 0.185 μg/mL had the best rate of growth 
inhibition of 36.31%. All results of the experiment revealed that the recombinant protein 
RPL23A exhibited anti-cancer function on the Hep-2 cells. The study provides a scientific 
basis and aids orientation for the research and development of cancer protein drugs as well 
as possible anti-cancer mechanisms. Further research is on going to determine the bioactive 
principle(s) of recombinant protein RPL23A responsible for its anticancer activity. 
Keywords: Giant Panda;  RPL23A; cDNA; cloning; overexpression; purification; 
anticancer activity 
 
1. Introduction 
Ribosomes, the organelles that catalyze protein synthesis, consist of a small 40S subunit and a  
large 60S subunit. Together these subunits are composed of 4 RNA species and approximately   
80 structurally distinct proteins [1,2]. The RPL23A gene encodes a ribosomal protein that is a 
component of the 60S subunit. The protein belongs to the L23P family of ribosomal proteins. It is 
located in the cytoplasm. As is typical for genes encoding ribosomal proteins, there are multiple 
processed pseudogenes of this gene dispersed through the genome [3]. 
Ribosomal protein gene mutations or disturbance in their expression levels have been found in 
many inherited genetic diseases such as Diamond-Blackfan anaemia syndrome, Tuner syndrome, 
Noonan syndrome, Camurati-Engelmann disease, and BardetBiedl syndrome 4. In recent years, along 
with progress in science technique with unremitting and continuous work going deep into research, the 
physiological function in the human disease of the ribosomal protein has been progressively   
clarified [4]. Some achievements show that the RPL23A gene has been playing a role in cell growth 
and regulation. A component of ribosomal proteins, human ribosomal protein L23A (RPL23A), 
identified as mda20, is one of the genes down-regulated in human melanoma and other cell types 
treated with IFN-b. So the RPL23A protein may be one of the target molecules involved in mediating 
growth inhibition by interferon [5]. In yeast, the corresponding protein binds to a specific site on the 
26S rRNA. The RPL23A gene is co-transcribed with the U42A, U42B, U101A, and U101B small 
nucleolar RNA genes, which are located in its third, first, second, and fourth introns, respectively [6]. 
Another study found that the ribosomal proteins L23A can each be imported alternatively by any of the 
importinβ, transportin, RanBP5 and RanBP7 receptors. RPL23A has been studied in detail and a very 
basic region to which each of the four import receptors bind avidly has been identified. This domain 
might be considered as an archetypal import signal that evolved before import receptors diverged in 
evolution [7]. 
Cancer is one of the leading causes of mortality worldwide. Cancer, known medically as a 
malignant neoplasm, is a term for a large group of different diseases, all involving unregulated cell 
growth [8]. In cancer, cells divide and grow uncontrollably, forming malignant tumors, and invade 
neighbouring parts of the body. The cancer may also spread to more distant parts of the body through Int. J. Mol. Sci. 2012, 13                 
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the lymphatic system or bloodstream [9]. Cancer is one of the most fatal diseases in the human 
population and one of the most frequent causes of death worldwide [10,11]. Many proteins possess 
antitumor activity. The present study was carried out to evaluate the anti-cancer activity of 
Ribosomal Protein L23A (RPL23A) from the Giant Panda. 
At present, the sequence information for RPL23A gene has been reported in other fields [5,6,12]. 
However, RPL23A gene from the Giant Panda (A. melanoleuca) has not been reported, especially in 
aspect of anti-cancer function. The Giant Panda (A. melanoleuca) is one of the oldest and rarest species, 
currently found only in China, and known as the “National treasure of China”. It belongs to the most 
endangered species in the world. In the past years, scientists have achieved tremendous success with 
the macrograph of the Giant Panda. Recently, functional gene study became one of the hottest issues in 
current Giant Panda research [13–20]. Now we are paying more attention to ribosomal protein 
RPL23A of the Giant Panda because of its many biological functions especially in relation to 
anticancer activity. 
In this study, according to the related information for ribosomal protein L23A gene (RPL23A) of the 
designed primer of some mammalians, including Homo sapiens, Mus musculus, Rattus norvegicus and 
Macaca mulatta, we used RT-PCR technique to amplify the cDNA of RPL23A gene from the total 
RNA of the skeleton muscle of the Giant Panda. We then analyzed the sequence characteristics of the 
protein encoded by the cDNA and compared it with those of human and other animals reported. We 
constructed a recombinant expression vector contained RPL23A cDNA and over-expressed it in E. coli 
using pET28a plasmids. Under the optimized expression conditions, we obtained a lot of recombinant 
protein of RPL23A from the Giant Panda, which then was purified using Ni chelating affinity 
chromatography. Recombinant protein obtained from the experiment acted on human laryngeal 
carcinoma Hep-2 cells and human hepatoma HepG2 cells, then displayed a different cell growth 
depressive effect. The present study was carried out to evaluate the anti-cancer activity of 
ribosomal protein L23A (RPL23A) from the Giant panda on human laryngeal carcinoma Hep-2 cells 
and human hepatoma HepG2 cells. The purpose is to reveal the anti-cancer activity of 
ribosomal protein L23A (RPL23A) from the Giant panda. The study will provide scientific data and 
means for postulating the anti-cancer mechanism, for pharmaceutical research and for the development 
of the gene from the Giant Panda. 
2. Results and Discussion 
2.1. Analysis of the cDNA of RPL23A from the Giant Panda 
About 500 bp of cDNA fragment was amplified from the Giant Panda. The length of the cDNA 
cloned was 506 bp (Figure 1). 
On the basis of the high identity, we concluded that the cDNA isolated is the cDNA encoding the 
Giant Panda RPL23A protein. The RPL23A sequence was submitted to Genbank (accession number: 
HQ318070). The 506 bp of the Giant Panda RPL23A sequence contains a 13 bp 5’- untranslated 
sequence and a 22 bp 3’-unstranslated region. An open-reading frame (ORF) of 471 bp encoding  
156 amino acids was found in the cDNA sequence (Figure 2). Int. J. Mol. Sci. 2012, 13                 
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Alignment analysis of RPL23A of the Giant Panda and those of Homo sapiens, Mus musculus, 
Rattus norvegicus and Macaca mulatta, indicated that both the nucleotide sequence and the deduced 
amino acid sequence are highly conserved. There is no deletion or insertion of nucleotide and amino 
acid residue. As determined by BLAST analysis, the nucleotide sequence RPL23A cloned from the 
Giant Panda shares a high homology with those of Homo sapiens, Mus musculus, Macaca mulatta and 
Rattus norvegicus of 90.02%, 88.96%, 91.30% and 88.32%, respectively; the homologies for amino 
acid sequences are all 99.87% compared with the four species. This striking pattern of evolutionary 
conservation is considered reasonable, as ribosomal protein genes are a group of highly conserved 
housekeeping genes [21]. 
Figure 1. Reverse transcription polymerase chain reaction products of the Giant Panda 
RPL23A. M: Molecular Marker DL2000; 1, 2: amplified RPL23A. 
 
Figure 2. Nucleotide and deduced amino acid sequences of cDNA encoding the Giant 
Panda RPL23A. The asterisk (*) represents stop codon. 
 
2.2. Prediction and Analysis of Primary Structure, Protein Functional Sites and Advanced Structure in 
RPL23A Protein of the Giant Panda 
Primary structure analysis revealed that the molecular weight of the putative RPL23A protein of the 
Giant Panda is 17.7179 kDa with a theoretical pI 11.16 (Table1). Like most ribosomal proteins, L23A Int. J. Mol. Sci. 2012, 13                 
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is highly basic, containing a combined 45 Arg, Lys, and His residues and only 14 Asp and Glu 
residues, in which the highest content is the Lys residues (19.23%), far higher than other amino acids 
and without Cyc and Trp residues. Physical and chemical analysis showed that the molecular weight of 
the putative protein among the five mammalians is very close and the theoretical pI is identical   
(Table 1). The secondary structure analysis of RPL23A protein indicated that the protein was 15.38% 
in E (strand), 44.87% in H (helix) and 39.74% in C (coil). The secondary structure is slightly different 
compared with Homo sapiens, Macaca mulatta, Mus musculus and Rattus norvegicus (Table 2). 
Table 1. The comparison of molecular weight and PI of  RPL23A protein between   
A. melanoleuca and other four species. 
 
Ailuropoda 
melanoleuca
Homo 
sapiens 
Mus 
musculus
Rattus 
norvegicus 
Macaca 
mulatta 
Molecular weight (kD)  17.7179  17.6919  17.6919  17.6919  17.6919 
PI  11.16  11.16  11.16  11.16  11.16 
Table 2. The differences in  secondary structure of RPL23A protein between the   
A. melanoleuca and other four species. 
Species 
amino acid site 
123  126  127  128  129  130 
A. melanoleuca  H  H  H  H  H  H 
Homo sapiens  H  H  H  H  H  H 
Mus musculus  C  H  H  H  H  H 
Rattus norvegicus  C  H  H  H  H  H 
Bos Taurus  H  C  C  C  C  C 
Topology prediction shows that there is one N-glycosylation site, one Tyrosine kinase 
phosphorylation site, three Protein kinase C phosphorylation sites and one Ribosomal protein L23 
signature in the RPL23A protein of the Giant Panda (A. melanoleuca) (Figure 3). Further analysis 
detected only one polymorphic site in the amino acid sequences of the five species compared   
(Figure 3). Site 5 is a Pro in the Giant Panda, but the other mammals have an Ala at this site. This 
polymorphism of C-to-G and T-to-G synonymous mutation, were detected at the first and third base of 
codon 5 (CCT→GCG, Pro→Ala) in the Giant Panda. But this polymorphic site is not located in the 
functional site, so it does not result in any differences between the Giant Panda and the other four 
species. Also, most base transitions of the gene coding sequence in these mammals were synonymous 
mutations. These synonymous mutations did not result in any changes in the corresponding DNA 
information and did not change the amino acid in the expression product. Consequently the spatial 
structure of the corresponding protein is not affected. Int. J. Mol. Sci. 2012, 13                 
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Figure 3. Comparison of the RPL23A amino acid sequences among the different species.  
        : N-glycosylation site;    : Protein kinase C phosphorylation site;    : Tyrosine kinase 
phosphorylation site;    : Ribosomal protein L23 signature;     : polymorphism site.   
(Pa:  A. melanoleuca; Ho: Homo sapiens;  Mu: Mus musculus; Ra: Rattus norvegicus;  
Ma: Macaca mulatta). 
 
2.3. Overexpression and Purification of the RPL23A Gene in E. coli 
The RPL23A gene was overexpressed in E. coli, using pET28a plasmids carrying strong promoter 
and terminator sequences derived from phage T7. For this purpose, the RPL23A gene was amplified 
individually by PCR and cloned in a pET28a plasmid, resulting in a gene fusion coding for a protein 
bearing a His-tag extension at the N terminus. Expression was tested by SDS-PAGE analysis of 
protein extracts from recombinant in E. coli BL21 strains (Figure 4). The results indicated that the 
protein RPL23A fusion with the N-terminally His-tagged form gave rise to the accumulation of an 
expected 22 kDa polypeptide that formed inclusion bodies. Apparently, the recombinant protein was 
expressed after half an hour of induction and after 3.5 h reached the highest level. The expression 
product obtained could be used for purification and further study of its function. 
Under the optimized expression conditions, we obtained a lot of recombinant protein, which then 
was purified by using Ni-NTA chelating affinity chromatography. SDS-PAGE analysis clearly 
indicated that there are about 22 kDa polypeptides in the third and fourth lanes (Figure 5). Protein 
separation and purification are key steps in genetic engineering technology. Through affinity 
chromatography, we obtained purified protein. During affinity chromatography, the protein solution 
PH was changed twice which enabled us to achieve a high purity of protein. It means that the protein 
solution firstly goes through the column under acid conditions, and then finally outflows from the 
column by changing the PH of the effluent liquid. SDS-PAGE analysis clearly indicated that there are Int. J. Mol. Sci. 2012, 13                 
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about 22 kDa polypeptides in the third and fourth lane. Size consistency of the purified protein and 
unpurified RPL23A protein suggest that the protein is only the protein encoded by the RPL23A from 
the Giant Panda. The sequence of acquired ribosomal protein RPL23A gene recombinant protein from 
the Giant Panda consists of 190 amino acid residues. The molecular weight of recombinant protein 
RPL23A was 21.265 kDa and the PI was 10.57. 
Figure 4. Protein extracted from recombinant E. coli strains were analyzed by SDS-PAGE 
gel stained with Commassie blue R 250. Numbers on right shows the molecular weight, 
and the arrow indicates the recombinant protein bands induced by IPTG with 0, 0.5, 1, 1.5, 
2, 2.5, 3and 3.5 h (lane 2–9), respectively. The lane 1 represents the products of the E. coli 
strains with the empty vectors. 
 
Figure 5. The purification of recombinant proteins RPL23A (Lane 1: RPL23A proteins 
extracted from recombinant E. coli; Lane 2: effluent liquid collected from columns; Lane 
3–8: the eluent collected from columns). 
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2.4. Anticancer Activity of Ribosomal Protein L23A (RPL23A) from the Giant Panda on Human 
Laryngeal Carcinoma Hep-2 cells and Human Hepatoma HepG2 Cells 
Laryngeal cancer may also be called cancer of the larynx or laryngeal carcinoma. Most laryngeal 
cancers are squamous cell carcinomas, reflecting their origin from the squamous cells which form the 
majority of the laryngeal epithelium. Laryngeal cancer may spread by direct extension to adjacent 
structures, by metastasis to regional cervical lymph nodes, or more distantly, through the blood stream. 
Distant metastates to the lung are most common [22]. A hardy cell line, HEp-2 resists temperature, 
nutritional, and environmental changes without a loss of viability. It has supported the growth of 10 of  
14 arboviruses as well as the measles virus, and it has been used for experimental studies of tumor 
production in rats, hamsters, mice, embryonated eggs and volunteer terminal cancer patients [23,24]. 
HepG2 (Hepatocellular carcinoma, human) cells are epithelial in morphology, and secrete a variety of 
major plasma proteins; e.g., albumin, transferrin and the acute phase proteins fibrinogen, alpha   
2-macroglobulin, alpha 1-antitrypsin, transferrin and plasminogen [25]. Our experiments gave different 
results because of the differences between these two kinds of cancer cells. 
Figure 6. Cell growth inhibition of Ribosomal Protein L23A (RPL23A) from Giant Panda 
on human laryngeal carcinoma Hep-2 cells and human hepatoma HepG-2 cells (1–8: The 
concentration of recombinant protein RPL23A of 0, 7.4, 2.96, 1.48, 0.74, 0.37, 0.185, 
0.148 μg/mL, respectively). 
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To assess whether the recombinant protein RPL23A demonstrates anticancer activity in human 
laryngeal carcinoma Hep-2 cells and human hepatoma HepG2 cells, these cells were then cultured in 
the presence and absence of various concentrations of the RPL23A for 24 h. The human laryngeal 
carcinoma Hep-2 cells and human hepatoma HepG2 cells treated with 0.148–7.4 μg/mL of RPL23A 
for 24 h displayed different cell growth inhibition when assayed using MTT compared to the control Int. J. Mol. Sci. 2012, 13                 
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(untreated) cells. For comparison, human hepatoma HepG-2 cells displayed no significant change 
when compared to the control (untreated) cells, while the RPL23A has a time and dose dependent on 
Hep-2 cell growth inhibition. The data indicate that the effect at low concentrations is better than at 
high concentrations, and the concentration of 0.185 μg/mL has the best rate of growth inhibition, 
which is 36.31% (Figure 6). The proliferation of human laryngeal carcinoma hep-2 cells was thus 
restrained by recombinant protein RPL23A. The principle may be that there are some RPL23A 
receptors on the face of the human laryngeal carcinoma hep-2 cells, which combine with recombinant 
protein RPL23A. Further studies of the mechanism and the signal transduction pathways are   
in progress. 
2.5. The effect of Ribosomal Protein L23A (RPL23A) from the Giant Panda on Morphology of Human 
Laryngeal Carcinoma Hep-2 cells 
The 96-well plates were placed under inverted microscope; the camera records different 
concentration changes for cell morphology in order to measure the effect of recombinant protein 
RPL23A. RPL23A exhibited high anticancer activity as can be seen from the cell morphology which 
was rounded into groups, and even cracked off in pieces in the Hep-2 group, while Hep G-2 cells 
displayed no significant change compared to those in the control group (data not shown) (Figure 7). 
Figure 7. The effect of Ribosomal  Protein  L23A (RPL23A)  from  the Giant Panda on 
morphology of human laryngeal carcinoma Hep-2 cells for 0, 7.4, 2.96, 1.48, 0.74, 0.37, 
0.185, 0.148 μg/mL (pictures 1–8), respectively. 
 
(10 × 20) 
3. Experimental Section 
3.1. Materials 
Skeletal muscle was collected from a dead Giant Panda at the Wolong Conservation Center of the 
Giant Panda (Sichuan, China). The collected skeletal muscle was frozen in liquid nitrogen and then Int. J. Mol. Sci. 2012, 13                 
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used for RNA isolation. The human laryngeal carcinoma Hep-2 cells were bought in the biochemistry 
and molecular immune research institute of North Sichuan Medical College. Total Tissue/cell RNA 
Extraction Kits were purchased from Waton Company (Shanghai, China). Reverse transcription kits 
were from Promega Company (Beijing, China). Gel Extraction Mini Kits were purchased from 
OMEGA Corporation (Shanghai, China). PMD-18 T Vector Systems and restriction enzyme BamHI 
and HindⅢ were got from TaKaRa Bio Group (Dalian, China). DNA polymerases were purchased 
from Sangon Co (Shanghai, China). Host bacteria E. coli DH5α were stored in Key Laboratory of 
Southwest China Wildlife Resources Conservation. CW0009 Ni-Agarose His-tag Protein purification 
kits were purchased from Ealysino Biological Technology Co. (Beijing, China). Bradford Protein Assay 
Kits were purchased from Majorbio Biotech Co. (Shanghai, China).Penicillin/streptomycin (penicillin 
10,000 units/mL, streptomycin 10,000 μg/mL) and Dulbecco’s minimal essential medium (DMEM) 
reagents were purchased from Gibco BRL (Grand Island, NY, USA). Fetal bovine serum was obtained 
from Sijiqing Co. (Guangzhou, China). 
3.2. RNA Isolation 
Total RNAs were isolated from about 600mg of muscle tissue using the Total Tissue/Cell RNA 
Extraction Kits (Waton Inc., Shanghai, China) according to the manufacturer’s instructions. The total 
RNAs extracted were dissolved in DEPC (diethypyrocarbonate) water, and kept at −70℃. 
3.3. Primers Design, RT-PCR 
The PCR primers were designed by Primer Premier 5.0, based on the mRNA sequence of RPL23A 
from Homo sapiens (NM_000984), Mus musculus (NM_207523), Rattus norvegicus (NM_001108283) 
and Macaca mulatta (NM_001193565). The specific primers of cDNA sequence are as follows: 
Pd-RPL23A-F: 5’-CCTTTTCGACAAGATGGCG-3’; 
Pd-RPL23A-R: 5’-GAATTAGCCAGCTGGACTCA-3’. 
Total RNAs were synthesized into the first-stranded cDNAs using a reverse transcription kit with 
Oligo dT as the primers, according to the manufacturer’s instructions (Promega, Beijing, China). The  
20 μL of first-strand cDNA synthesis reaction system included 1 μg of total RNAs, 5 mM of MgCl2,  
1 mM of dNTPs, 0.5 μg of Oligo dT15, 10 U/μL of RNase inhibitor, and 15U of AMV reverse 
transcriptase, and was incubated at 42 °C for 60 min. 
The first-strand cDNA synthesized was used as a template. The total reaction volume for DNA 
amplification was 25 μL. Reaction mixtures contained 1.5 mM of MgCl2, 200 μM of each of dATP, 
dGTP, dCTP and dTTP (Omega,  Kanpur, India), 0.3 μM of each primer, 5.0 units of Taq plus DNA 
polymerase (Sangon Co., Shanghai, China). DNA amplification was performed using a MJ Research 
thermocycler, Model PTC-200 (Watertown, MA, USA) with a program of 4 min at 94.0 °C, followed 
by 30 cycles of 1 min at 94.0 °C, 0.5 min at 46 °C and 1.5 min at 72.0 °C, and then ended with the 
final extension for 10 min at 72.0 °C. After amplification, PCR products were separated by 
electrophoresis in 1.5% agarose gel with 1× TAE (Tris-acetate-EDTA) buffer, stained with ethidium 
bromide and visualized under UV light. The expected fragments of PCR products were harvested and 
purified from gel using a DNA harvesting kit (Omega, Kanpur, India), and stored at −20°C. Int. J. Mol. Sci. 2012, 13                 
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3.4. Cloning and Identifying the cDNA Sequence 
The harvested PCR products were ligated into a pMD19-T  vector at 4 °C for 12 h. The 
recombinant molecules were transformed into E. coli complete cells (DH5α), and then spread on the 
LB-plate containing 50 μg/mL ampicillin, 200 mg/mL IPTG (isopropyl-beta-D-thiogalactopyranoside), 
and 20 mg/mL X-gal. Plasmid DNA was isolated and digested by PstI and ScaII to verify the insert 
size. Plasmid DNA was sequenced by Huada Zhongsheng Scientific Corporation (Beijing, China). 
3.5. Construction of the Expression Vector and Overexpression of Recombinant RPL23A 
PCR fragment corresponding to the RPL23A polypeptide was amplified from the RPL23A cDNA 
clone with the forward primer, 5’-CAGAATTCATGGCGCCGAAG C-3’ (EcoRI) and reverse primer, 
5’- CGGTCGACTTAGATGATCCCA-3’ (SalI), respectively. The PCR was performed at 94 °C for  
3 min; 35 cycles of 30 s at 94 °C, 45 s at 53 °C and 1 min at 72 °C; 10 min at 72 °C. The amplified 
PCR product was cut and ligated into the corresponding site of pET28a vector (Stratagen). The 
resulting construct was transformed into E.coli BL21 (DE3) strain (Novagen) and used for the 
induction by adding IPTG (isopropyl-b-D-thiogalactopyranoside) at an OD600 of 0.6 and culturing 
further for 4 h at 37 °C, using the empty vector transformed BL21 (DE3) as a control. The recombinant 
protein samples were induced after 0, 0.5, 1, 1.5, 2, 2.5, 3 and 3.5 h and then separated by SDS-PAGE 
and stained with Commassie blue R 250. 
3.6. Purification of Recombinant Protein RPL23A  
Acquired genetic engineering recombinant protein has a tag which is comprised of six histidine 
(His-tag), so nickel chelating affinity chromatography is available as follows. Centrifuge the ultrasonic 
product to collect sediments, and then suspend them with Soluble Binding Buffer (20 mM Tris-HCl, 
0.5 M NaCl, 10 mM imidazole, pH 7.9) until the inclusion body is clean. Centrifuge and suspend the 
sediments with Inclusion Body Binding Buffer (20 mM Tris-HCl, 0.5 M NaCl, 5 mM imidazole, urea 
8 M, pH 7.9) in the ice, until the inclusion body is thoroughly dissolved. Centrifuge and transfer the 
above supernatant to the chromatography column with nickel. Stand for 2 min after the above 
supernatant is completely transferred so that the six His-tag and nickel in the padding can combine 
fully. Inclusion Body Binding Buffer of 15 times the column volume is used to flush the column, so as 
to wash the uncombined protein. Collect the excurrent liquid. Then, inclusion Body Elution Buffer of  
5 times the column volume is used to wash the combined protein. According to the amount of the 
column volume, collect the outflow liquid. Then, SDS-PAGE is used to detect the effect of purification. 
The concentration of recombinant protein is determined by Bradford Protein Assay Kits. To further 
purify the elution protein, dialysis is available. After 48 h of desalination, the purified protein with 
10% glycerol is stored at −20 °C. 
3.7. Cell Lines Culture 
Human laryngeal carcinoma Hep-2 cells and human hepatoma HepG-2 cells were purchased from 
North Sichuan Medical College, Institute of Biochemistry and Molecular Immunology and maintained 
for study in MEM (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS, Int. J. Mol. Sci. 2012, 13                 
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Evergreen biological Products company, Shanghai, China), 100 U/mL penicillin (Gibco Company, 
Billings, USA), 100 μg/mL streptomycin (Gibco Company, Billings, USA), pH 7.4 RPMI-1640(Gibco 
Company, Billings, USA) Cells were cultured in a 5% CO2/95% air incubator at 37 °C. 
3.8. Test the Cell Viability of Purified Recombinant Protein RPL23A on Human Laryngeal Carcinoma 
Hep-2 Cells and Human Hepatoma HepG-2 Cell Activity by MTT Assay  
These cells were seeded into 96-well microculture plates at appropriate densities to maintain the 
cells in an exponential phase of growth throughout the duration of the experiment. Human laryngeal 
carcinoma Hep-2 and human hepatoma HepG-2 cells were exposed to RPL23A protein at 0, 7.4, 2.96, 
1.48, 0.74, 0.37, 0.185, 0.148 µg/mL for 24 h and each concentration was evaluated in six separate 
wells, respectively. At the end of the exposure, 10 µL of MTT was added to each well and the plates 
were incubated for 4 h at 37 °C. Then, 150 µL of DMSO was added to each well and the plates were 
surged for 5 min.The optical density (OD) was read on a plate reader (BIO-RAD Co., Beijing, China) 
at two wavelengths of 490 nm. Media-alone as well as control wells, in which PMBE was absent, were 
included in all experiments. The degree of inhibition of cell proliferation was calculated using the 
following formula: Growth inhibition (%) = (OD control − OD treated)/OD control × 100%. 
3.9. Data Analysis  
The sequence data were analyzed by GenScan software (http://genes. mit.edu/ GENSCAN.html). 
Homology research of the Giant Panda RPL23A compared with the gene sequences of other species 
was performed using Blast 2.1 (http://www.ncbi. nlm.nih.gov/blast/). ORF of the DNA sequence was 
searched using ORF finder software (http://www.ncbi.nlm.nih.gov/gorf/gorf.html). The values of WM 
and pI were computed using the Compute pI/Mw tool (http://www.expasy.org/tools/pi_tool.html). 
Protein structure of the RPL23A sequence cloned was analyzed using PredictProtein software 
(http://cubic.Bioc.columbia.edu/predictprotein/). Multiple Sequence Alignment was performed by 
software DNAstar Lasergene and DNAMAN 6.0. 
4. Conclusions 
The results indicated that the length of fragment cloned is 506 bp, and that it contains an   
open-reading frame (ORF) of 471 bp encoding 156 amino acids. Primary structure analysis revealed 
that the molecular weight of the putative RPL23A protein is 17.719 kDa with a theoretical pI 11.16. 
The molecular weight of the recombinant protein RPL23A is 21.265 kDa with a theoretical pI 10.57. 
The RPL23A gene can be really expressed in E. coli and the RPL23A protein, fusioned with the  
N-terminally His-tagged protein, gave rise to the accumulation of an expected 22 KDa polypeptide. 
The data showed that the recombinant protein RPL23A had a time- and dose-dependency on the cell 
growth inhibition rate. The data also indicated that the effect at low concentrations was better than at 
high concentrations on Hep-2 cells, and the concentration of 0.185 μg/mL had the best rate of growth 
inhibition of 36.31%. For comparison, human hepatoma HepG-2 cells displayed no significant change 
when compared to the control (untreated) cells. Int. J. Mol. Sci. 2012, 13                 
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In recent years, more and more research has indicated that the high level expression of ribosomal 
protein is a prognostic factor in some kinds of tumor, and several ribosomal proteins have been 
identified in high levels in cancers [26–30]. Our research showed that ribosomal protein L23A can 
effectively inhibit human laryngeal carcinoma Hep-2 cells growth or proliferation activity. The 
findings will give scientific support and orientation for research and development of anticancer protein 
drugs of ribosomal protein L23A recombinant protein and for the development of tumor vaccine for  
tumor prevention. 
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